Rabusertib (LY2603618)

Catalog No.S2626 Synonyms: IC-83

Rabusertib (LY2603618) Chemical Structure

Molecular Weight(MW): 436.3

Rabusertib (LY2603618) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated.

Size Price Stock Quantity  
In DMSO USD 300 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 13 Publications

7 Customer Reviews

  • MK-1775 and LY2603618 synergize to induce apoptosis in AML cell lines and primary patient samples. U937 and CTS cells were treated for 8 h. Whole cell lysates were subjected to Western blotting and probed with anti-γH2AX, -pCHK1, -p-cdc25c, -p-CDK1, -p-CDK2, -CDK1, or -β-actin antibody. Densitometry measurements, as described in the Materials and methods section, are shown below the corresponding Western blot.

    J Hematol Oncol 2014 7, 53. Rabusertib (LY2603618) purchased from Selleck.

  • BxPC-3 cells were treated with vehicle control, MK-1775 (MK), LY2603618 (LY) or MK-1775 plus LY2603618 for 48 h. Protein extracts were subjected to Western blotting and probed with anti-PARP, -p-CHK1, -CHK1, -p-CDC25C, -p-CDK1, -CDK1, -p-CDK2, -CDK2, -γH2AX, or -β-actin antibody.

    Cancer Lett 2014 10.1016/j.canlet.2014.10.015. Rabusertib (LY2603618) purchased from Selleck.

  • Biomarker changes induced in response to gemcitabine plus Chk1 inhibitor treatment in HT29 colon carcinoma cells. HT29 colon cancer cells were exposed to 50 nM gemcitabine (+) for 16 hours followed by increasing concentrations of Chk1 inhibitor for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Rabusertib (LY2603618) purchased from Selleck.

  • C6 cell was trypsinized and plated at 30% confluence in DMEM. 16 hours later, LY2603618 was added at final concentrations of 0, 1, 5, 10 and 20uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using pS345-CHK1, g-H2AX and beta-actin (internal control) antibodies.

    Customer W, F. Z. Rabusertib (LY2603618) purchased from Selleck.

  • Hela cell was trypsinized and plated at 30% confluence in DMEM. 16 hours later, LY2603618 was added at final concentrations of 0, 5, 10 and 25uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- CHK1, pS345-CHK1 and beta-actin (internal control) antibodies.

    Rabusertib (LY2603618) purchased from Selleck.

  • (E) EW8 cells were treated with 50 nM gemcitabine in combination with increasing doses of prexasertib, LY2603618, or MK-8776 for 6 hours. Cell lysates were then collected and blotted for p-CHK1-296.

    Mol Cancer Ther, 2018, 17(12):2676-2688. Rabusertib (LY2603618) purchased from Selleck.

  • Oncol Rep, 2018, 39(3):1322-1330. Rabusertib (LY2603618) purchased from Selleck.

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description Rabusertib (LY2603618) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated.
Targets
Chk1 [1]
(Cell-free assay)
7 nM
In vitro

Chk1 is an ATP-dependent serine-threonine kinase and a key component in the DNA replication-monitoring checkpoint system activated by double-stranded breaks (DSBs). Chk1 contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint. By inhibiting the activity of chk1, LY2603618 prevents the repair of DNA caused by DNA-damaging agents, thus potentiating the antitumor efficacies of various chemotherapeutic agents. However, preclinical data involving LY2603618 has not been published until now. [1] Inhibition of Chk1 is predicted to enhance the effects of antimetabolites, such as gemcitabine. [2] LY2603618 treatment impairs DNA synthesis, increases DNA damage (via mitotic defects), induces apoptosis, and has synergistic activity with pemetrexed, especially in p53 mutant tumor cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT474 MX3LbY5ie2ViYYPzZZk> NFXaVmoyKM7:TR?= M4PTS2ROW09? MX3pcohq[mm2czDQMWNJUzFibHX2[Yx{ MYiyN|kyPzN5OB?=
MCF7 MoexT4lv[XOnIHHzd4F6 MontNUDPxE1? MWfEUXNQ M1vlTYlvcGmkaYTzJHAuS0iNMTDs[ZZmdHN? Ml;VNlM6OTd|N{i=
Hela NGfjSVZMcW6jc3WgZZN{[Xl? NYn5[Xg{OzNyMDDuUS=> NIj3bmpFVVOR M1yzeolvcGmkaYTzJGNpczFiYXP0bZZqfHl? NVTs[llvOjRzMUSxNlQ>
Calu6 NYrqTJI3U2mwYYPlJIF{e2G7 Mm\4N|MxOCCwTR?= MkfPSG1UVw>? NYSzepQ4cW6qaXLpeJMhS2itMTDhZ5Rqfmm2eR?= NF\pWJUzPDFzNEGyOC=>
A549 NYTWe4ZwTnWwY4Tpc44h[XO|YYm= NGLiVVd,OTBizszN NVHjWlVpTE2VTx?= NXnQ[GwzcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=> NFrKN|kzPDl{OEKwOS=>
H1299 MVvGeY5kfGmxbjDhd5NigQ>? NHjVUlJ,OTBizszN NFzUVmVFVVOR MoDmbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dB?= NUiwUJVkOjR7MkiyNFU>
A549 M{nwWWZ2dmO2aX;uJIF{e2G7 Mn7LglIxKM7:TR?= NI\XTWRFVVOR MoexZYN1cX[jdHXzJGRPSSCmYX3h[4Uhe2Wwc3;yJItqdmG|ZYO= NETwTWkzPDl{OEKwOS=>
H1299 NFjNRXZHfW6ldHnvckBie3OjeR?= MYr+NlAh|ryP NWP6U45kTE2VTx?= MoLxZYN1cX[jdHXzJGRPSSCmYX3h[4Uhe2Wwc3;yJItqdmG|ZYO= MX6yOFkzQDJyNR?=
A549 MWTBdI9xfG:|aYOgZZN{[Xl? MnrSglIxKM7:TR?= NFn2bZdFVVOR NWjPdnA3cW6mdXPld{BieG:ydH;zbZM> NV\4cXI{OjR7MkiyNFU>
H1299 NUj6OHNVSXCxcITvd4l{KGG|c3H5 MX3+NlAh|ryP MlPGSG1UVw>? MlTQbY5lfWOnczDhdI9xfG:|aYO= NHvzR5gzPDl{OEKwOS=>
A549 NGnZcIZEgXSxeHnjbZR6KGG|c3H5 M{TXd54zOCEQvF2= MV;EUXNQ NXzUdpFRcW6mdXPld{BifXSxcHjh[5k> M37mXlI1QTJ6MkC1
H1299 M1ntU2N6fG:6aXPpeJkh[XO|YYm= Mmi2glIxKM7:TR?= NETxPVBFVVOR MnnkbY5lfWOnczDheZRweGijZ4m= MX2yOFkzQDJyNR?=
A549 MYTGeY5kfGmxbjDhd5NigQ>? NITZSWt,OjBizszN NXHoSoJ6TE2VTx?= NY[wO|BIcW6lcnXhd4V{KEqQSzDhcoQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u NILGRXczPDl{OEKwOS=>
H1299 MkLxSpVv[3Srb36gZZN{[Xl? M4jx[J4zOCEQvF2= MoXuSG1UVw>? NWnMUVZ5cW6lcnXhd4V{KEqQSzDhcoQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u NIDQZW4zPDl{OEKwOS=>

... Click to View More Cell Line Experimental Data

In vivo In xenograft models, LY2603618 delays tumor growth when given in combination with pemetrexed. [3]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: A549 and H1299 cell
  • Concentrations: 5 or 10 μM
  • Incubation Time: 24 h
  • Method:

    Cells were treated with LY2603618 and DMSO as a control. After trypsinization, cells were fixed in 70 % ethanol at 4 C overnight. The cells were washed twice with PBS and incubated for 30 min in the dark in PBS containing propidium iodide (PI) and RNase A. Stained cells were analyzed by a FACScan flow cytometry and CellQuest analysis software.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL (29.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG400+0.5% Tween80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 436.3
Formula

C18H22BrN5O3

CAS No. 911222-45-2
Storage powder
in solvent
Synonyms IC-83

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01358968 Completed Cancer Eli Lilly and Company June 2011 Phase 1
NCT01358968 Completed Cancer Eli Lilly and Company June 2011 Phase 1
NCT01341457 Completed Solid Tumors Eli Lilly and Company May 2011 Phase 1
NCT01341457 Completed Solid Tumors Eli Lilly and Company May 2011 Phase 1
NCT01296568 Completed Advanced Cancer Eli Lilly and Company February 2011 Phase 1
NCT01139775 Completed Non Small Cell Lung Cancer Eli Lilly and Company February 2011 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products4

Tags: buy Rabusertib (LY2603618) | Rabusertib (LY2603618) supplier | purchase Rabusertib (LY2603618) | Rabusertib (LY2603618) cost | Rabusertib (LY2603618) manufacturer | order Rabusertib (LY2603618) | Rabusertib (LY2603618) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID